摘要
目的观察替莫唑胺(TMZ)对高级别胶质瘤的治疗效果。方法对2006年3月至2008年12月共计34例高级别的胶质瘤的住院手术后患者,按体表面积给予TMZ药物化疗。定期复查MRI,针对患者无进展生存时间以及生存时间做随访分析。结果 TMZ对术后的高级别胶质瘤(WHOⅢ级,Ⅳ级胶质瘤)患者单药化疗,平均肿瘤无进展生存时间为(10.08±6.4)个月,平均生存时间(12.06±6.25)个月。结论 TMZ作为新型烷化剂型抗肿瘤药物,能显著延长高级别胶质瘤患者的生存时间。
Objective To observe the therapeutic effect of Temozolomide （ TMZ） used for high-grade gliomas. Methods Used chemotherapy （ TMZ） for 34 inpatients after surgery who suffered high grade glioma from the March 2006 to December 2008,according to body surface area to give medicine,reviewed MRI regularly,and followed-up the patients for progression-free survival time and survival time,then analyzed . Results After the single-agent chemotherapy（ TMZ） for the patients who suffered high grade gliomas （ WHO Ⅲ,Ⅳ grade glioma） after surgery,the average survival time of tumor progression-free was （ 10. 08 ± 6. 4） months, the average survival time was （ 12. 06 ± 6. 25） months. Conclusion As a new alkylating agenttype anticancer drug,TMZ can significantly prolongs the survival time for the patients who suffere the high grade gliomas.
出处
《中国现代药物应用》
2011年第18期6-7,共2页
Chinese Journal of Modern Drug Application
关键词
替莫唑胺
脑肿瘤
化疗
疗效
Temozolomide （ TMZ）
Cerebral gliomas
Chemotherapy
Therapeutic effect
